A PHASE 1/2 OPEN-LABEL, MULTI-CENTER, SAFETY, PRELIMINARY EFFICACY AND PHARMACOKINETIC (PK) STUDY OF ISATUXIMAB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PARTICIPANTS WITH LYMPHOMA COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PARTICIPANTS WITH LYMPHOMA.
2018-002442-37LINFOMAFundación Jiménez DíazInvestigador: CORDOBA MASCUÑANO RAUL
